283 related articles for article (PubMed ID: 30072489)
1. Exploiting vulnerabilities in cancer signalling networks to combat targeted therapy resistance.
Harrison PT; Huang PH
Essays Biochem; 2018 Oct; 62(4):583-593. PubMed ID: 30072489
[TBL] [Abstract][Full Text] [Related]
2. Combined HSP90 and kinase inhibitor therapy: Insights from The Cancer Genome Atlas.
Schwartz H; Scroggins B; Zuehlke A; Kijima T; Beebe K; Mishra A; Neckers L; Prince T
Cell Stress Chaperones; 2015 Sep; 20(5):729-41. PubMed ID: 26070366
[TBL] [Abstract][Full Text] [Related]
3. Emergence of resistance to tyrosine kinase inhibitors in non-small-cell lung cancer can be delayed by an upfront combination with the HSP90 inhibitor onalespib.
Courtin A; Smyth T; Hearn K; Saini HK; Thompson NT; Lyons JF; Wallis NG
Br J Cancer; 2016 Oct; 115(9):1069-1077. PubMed ID: 27673365
[TBL] [Abstract][Full Text] [Related]
4. Overcoming acquired resistance to HSP90 inhibition by targeting JAK-STAT signalling in triple-negative breast cancer.
Mumin NH; Drobnitzky N; Patel A; Lourenco LM; Cahill FF; Jiang Y; Kong A; Ryan AJ
BMC Cancer; 2019 Jan; 19(1):102. PubMed ID: 30678647
[TBL] [Abstract][Full Text] [Related]
5. Quantitative phosphoproteomic analysis of acquired cancer drug resistance to pazopanib and dasatinib.
Vyse S; McCarthy F; Broncel M; Paul A; Wong JP; Bhamra A; Huang PH
J Proteomics; 2018 Jan; 170():130-140. PubMed ID: 28842319
[TBL] [Abstract][Full Text] [Related]
6. Durability of Kinase-Directed Therapies--A Network Perspective on Response and Resistance.
Murray BW; Miller N
Mol Cancer Ther; 2015 Sep; 14(9):1975-84. PubMed ID: 26264276
[TBL] [Abstract][Full Text] [Related]
7. Mechanisms of Resistance to JAK2 Inhibitors in Myeloproliferative Neoplasms.
Meyer SC
Hematol Oncol Clin North Am; 2017 Aug; 31(4):627-642. PubMed ID: 28673392
[TBL] [Abstract][Full Text] [Related]
8. Plk1 Inhibitors in Cancer Therapy: From Laboratory to Clinics.
Gutteridge RE; Ndiaye MA; Liu X; Ahmad N
Mol Cancer Ther; 2016 Jul; 15(7):1427-35. PubMed ID: 27330107
[TBL] [Abstract][Full Text] [Related]
9. Hsp90 inhibitor as a sensitizer of cancer cells to different therapies (review).
Solárová Z; Mojžiš J; Solár P
Int J Oncol; 2015 Mar; 46(3):907-26. PubMed ID: 25501619
[TBL] [Abstract][Full Text] [Related]
10. A novel C-terminal Hsp90 inhibitor KU758 synergizes efficacy in combination with BRAF or MEK inhibitors and targets drug-resistant pathways in BRAF-mutant melanomas.
Sanchez JN; Subramanian C; Chanda M; Shanguan G; Zhang N; Wang T; Timmermann BN; Blagg BSJ; Cohen MS
Melanoma Res; 2021 Jun; 31(3):197-207. PubMed ID: 33904516
[TBL] [Abstract][Full Text] [Related]
11. Dissecting mechanisms of resistance to targeted drug combination therapy in human colorectal cancer.
Clarke PA; Roe T; Swabey K; Hobbs SM; McAndrew C; Tomlin K; Westwood I; Burke R; van Montfort R; Workman P
Oncogene; 2019 Jun; 38(25):5076-5090. PubMed ID: 30905967
[TBL] [Abstract][Full Text] [Related]
12. Drugging the cancer chaperone HSP90: combinatorial therapeutic exploitation of oncogene addiction and tumor stress.
Workman P; Burrows F; Neckers L; Rosen N
Ann N Y Acad Sci; 2007 Oct; 1113():202-16. PubMed ID: 17513464
[TBL] [Abstract][Full Text] [Related]
13. Targeting Hsp90 in urothelial carcinoma.
Chehab M; Caza T; Skotnicki K; Landas S; Bratslavsky G; Mollapour M; Bourboulia D
Oncotarget; 2015 Apr; 6(11):8454-73. PubMed ID: 25909217
[TBL] [Abstract][Full Text] [Related]
14. The HSP90 inhibitor ganetespib potentiates the antitumor activity of EGFR tyrosine kinase inhibition in mutant and wild-type non-small cell lung cancer.
Smith DL; Acquaviva J; Sequeira M; Jimenez JP; Zhang C; Sang J; Bates RC; Proia DA
Target Oncol; 2015 Jun; 10(2):235-45. PubMed ID: 25077897
[TBL] [Abstract][Full Text] [Related]
15. Principles of Resistance to Targeted Cancer Therapy: Lessons from Basic and Translational Cancer Biology.
Sabnis AJ; Bivona TG
Trends Mol Med; 2019 Mar; 25(3):185-197. PubMed ID: 30686761
[TBL] [Abstract][Full Text] [Related]
16. The HSP90 inhibitor ganetespib synergizes with the MET kinase inhibitor crizotinib in both crizotinib-sensitive and -resistant MET-driven tumor models.
Miyajima N; Tsutsumi S; Sourbier C; Beebe K; Mollapour M; Rivas C; Yoshida S; Trepel JB; Huang Y; Tatokoro M; Shinohara N; Nonomura K; Neckers L
Cancer Res; 2013 Dec; 73(23):7022-33. PubMed ID: 24121490
[TBL] [Abstract][Full Text] [Related]
17. The HSP90 inhibitor, NVP-AUY922, sensitizes KRAS-mutant non-small cell lung cancer with intrinsic resistance to MEK inhibitor, trametinib.
Park KS; Oh B; Lee MH; Nam KY; Jin HR; Yang H; Choi J; Kim SW; Lee DH
Cancer Lett; 2016 Mar; 372(1):75-81. PubMed ID: 26723875
[TBL] [Abstract][Full Text] [Related]
18. The Strange Case of CDK4/6 Inhibitors: Mechanisms, Resistance, and Combination Strategies.
Knudsen ES; Witkiewicz AK
Trends Cancer; 2017 Jan; 3(1):39-55. PubMed ID: 28303264
[TBL] [Abstract][Full Text] [Related]
19. Overcoming acquired BRAF inhibitor resistance in melanoma via targeted inhibition of Hsp90 with ganetespib.
Acquaviva J; Smith DL; Jimenez JP; Zhang C; Sequeira M; He S; Sang J; Bates RC; Proia DA
Mol Cancer Ther; 2014 Feb; 13(2):353-63. PubMed ID: 24398428
[TBL] [Abstract][Full Text] [Related]
20. Polytherapy and Targeted Cancer Drug Resistance.
Chatterjee N; Bivona TG
Trends Cancer; 2019 Mar; 5(3):170-182. PubMed ID: 30898264
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
